Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow SER by emailGet an email when SER pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SER, unsubscribe in one click. Privacy
📣 What SER Says Is Next
first half of 2027 · “The Company expects to report topline data from the single-ascending-dose portion of the study in the first half of 2027.”
Company press release, Sep 9, 2026 · SEC filing
first half of 2027 · “Top-line data from the single-ascending-dose arm remain targeted for the first half of 2027.”
Company press release, Aug 13, 2026 · SEC filing
first half of 2027 · ““Completion of Cohort 1 progresses the program to its next protocol-defined safety review and dose-escalation decision as we expect top-line data from the single-ascending-dose arm in the first half of 2027.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full SER picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SER and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.